A review of antibody-based therapeutics targeting G protein-coupled receptors: an update

References

• Almén MS, Nordström KJ, Fredriksson R, et al. Mapping the human membrane proteome: a majority of the human membrane proteins can be classified according to function and evolutionary origin. BMC Biol. 2009;7:50.
   PubMed Web of Science ®Google Scholar
• Santos R, Ursu O, Gaulton A, et al. A comprehensive map of molecular drug targets. Nat Rev Drug Discov. 2016;16:19–34.
   PubMed Web of Science ®Google Scholar
• Hauser AS, Attwood MM, Rask-Andersen M, et al. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16:829–842.
   PubMed Web of Science ®Google Scholar
• Lagerström MC, Schiöth HB. Structural diversity of G protein-coupled receptors and significance for drug discovery. Nat Rev Drug Discov. 2008;7:339–357.
   PubMed Web of Science ®Google Scholar
• Heng BC, Aubel D, Fussenegger M. An overview of the diverse roles of G-protein coupled receptors (GPCRs) in the pathophysiology of various human diseases. Biotechnol Adv. 2013;31:1676–1694.
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EY, Mol CD, et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science. 2010;330:1066–1071.
   PubMed Web of Science ®Google Scholar
• Coleman JL, Ngo T, Smith NJ. The G protein-coupled receptor N-terminus and receptor signalling: N-tering a new era. Cell Signal. 2017;33:1–9.
   PubMed Web of Science ®Google Scholar
• Bassilana F, Nash M, Ludwig MG. Adhesion G protein-coupled receptors: opportunities for drug discovery. Nat Rev Drug Discov. 2019;18:869–884.
   PubMed Web of Science ®Google Scholar
• Wheatley M, Wootten D, Conner MT, et al. Lifting the lid on GPCRs: the role of extracellular loops. Br J Pharmacol. 2012;165: 1688–170.
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors receptors. MAbs. 2010;2:594–606.
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Koglin M, Olson WC, et al. Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nat Rev Drug Discov. 2017;16:787–810.
   PubMed Web of Science ®Google Scholar
• Arimont M, Hoffmann C, de Graaf C, et al. Chemokine receptor crystal structures: what can be learned from them? Mol Pharmacol. 2019;96:765–777.
   PubMed Web of Science ®Google Scholar
• Dodd RB, Wilkinson T, Schofield DJ. Therapeutic monoclonal antibodies to complex membrane protein targets: antigen generation and antibody discovery strategies. BioDrugs. 2018;32:339–355.
   PubMed Web of Science ®Google Scholar
• Douthwaite JA, Finch DK, Mustelin T, et al. Development of therapeutic antibodies to G protein-coupled receptors and ion channels: opportunities, challenges and their therapeutic potential in respiratory diseases. Pharmacol Ther. 2017;169:113–123.
   PubMed Web of Science ®Google Scholar
• Ayoub MA, Crépieux P, Koglin M, et al. Antibodies targeting G protein-coupled receptors: recent advances and therapeutic challenges. MAbs. 2017;9:735–741.
   PubMed Web of Science ®Google Scholar
• Kuhne MR, Mulvey T, Belanger B, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013;19:357–366.
   PubMed Web of Science ®Google Scholar
• Yan H, Gu W, Yang J, et al. Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther. 2009;329:102–111.
   PubMed Web of Science ®Google Scholar
• van der Woning B, De Boeck G, Blanchetot C, et al. DNA immunization combined with scFv phage display identifies antagonistic GCGR specific antibodies and reveals new epitopes on the small extracellular loops. MAbs. 2016;8:1126–1135.
   PubMed Web of Science ®Google Scholar
• Amgen Inc XUC, Hamburger AE Human PAC1 antibodies. US20160039939
   Google Scholar
• Bradley ME, Dombrecht B, Manini J, et al. Potent and efficacious inhibition of CXCR2 signaling by biparatopic nanobodies combining two distinct modes of action. Mol Pharmacol. 2015;87:251–262.
   PubMed Web of Science ®Google Scholar
• Britton ZT, London TB, Carrell J, et al. Tag-on-Demand: exploiting amber codon suppression technology for the enrichment of high-expressing membrane protein cell lines. Protein Eng Des Sel. 2018;31:389–398.
   PubMed Web of Science ®Google Scholar
• Butler R, Hornigold D, Huang L, et al. Use of the site-specific retargeting jump-in platform cell line to support biologic drug discovery. J Biomol Screen. 2015;20:528–535.
   PubMedGoogle Scholar
• Dauvergne J, Desuzinges EM, Faugier C, et al. Glycosylated amphiphilic calixarene-based detergent for functional stabilization of native membrane proteins. ChemistrySelect. 2019;4:5535–5539.
   Google Scholar
• Scott DJ, Kummer L, Egloff P, et al. Improving the apo-state detergent stability of NTS1 with CHESS for pharmacological and structural studies. Biochim Biophys Acta. 2014;1838:2817–2824.
   PubMed Web of Science ®Google Scholar
• Schütz M, Schöppe J, Sedlák E, et al. Directed evolution of G protein-coupled receptors in yeast for higher functional production in eukaryotic expression hosts. Sci Rep. 2016;6:21508.
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Cseke G, Osborne G, et al. Monoclonal anti-β1-adrenergic receptor antibodies activate G protein signaling in the absence of β-arrestin recruitment. MAbs. 2014;6:246–261.
   PubMed Web of Science ®Google Scholar
• Heym RG, Hornberger WB, Lakics V, et al. Label-free detection of small-molecule binding to a GPCR in the membrane environment. Biochim Biophys Acta. 2015;1854:979–986.
   PubMed Web of Science ®Google Scholar
• Fowler KA, Vasilieva V, Ivanova E, et al. R707, a fully human antibody directed against CC-chemokine receptor 7, attenuates xenogeneic acute graft-versus-host disease. Am J Transplant. 2019;19:1941–1954.
   PubMed Web of Science ®Google Scholar
• Van Hout A, Klarenbeek A, Bobkov V, et al. CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry. Biochem Pharmacol. 2018;158:402–412.
   PubMed Web of Science ®Google Scholar
• Vasilca V, Sadeghpour A, Rawson S, et al. Spherical-supported membranes as platforms for screening against membrane protein targets. Anal Biochem. 2018;549:58–65.
   PubMed Web of Science ®Google Scholar
• Dominik PK, Borowska MT, Dalmas O, et al. Conformational chaperones for structural studies of membrane proteins using antibody phage display with nanodiscs. Structure. 2016;24:300–309.
   PubMed Web of Science ®Google Scholar
• Liu S, Wang S, Lu S. DNA immunization as a technology platform for monoclonal antibody induction. Emerg Microbes Infect. 2016;5:e33.
   PubMed Web of Science ®Google Scholar
• Huang CC, Cheng KW, Hsieh YC, et al. Use of syngeneic cells expressing membrane-bound GM-CSF as an adjuvant to induce antibodies against native multi-pass transmembrane protein. Sci Rep. 2019;9:9931.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wan Y, Tao P, et al. A cell-cell interaction format for selection of high-affinity antibodies to membrane proteins. Proc Natl Acad Sci U S A. 2019;116:14971–14978.
   PubMed Web of Science ®Google Scholar
• Wang J, An L, Zhao Y, et al. In vitro affinity maturation of antibody against membrane-bound GPCR molecules. Appl Microbiol Biotechnol. 2019;103:7703–7717.
   PubMed Web of Science ®Google Scholar
• Fonin AV, Darling AL, Kuznetsova IM, et al. Multi-functionality of proteins involved in GPCR and G protein signaling: making sense of structure-function continuum with intrinsic disorder-based proteoforms. Cell Mol Life Sci. 2019;76:4461–4492.
   PubMed Web of Science ®Google Scholar
• Caron MG, Barak LS. A brief history of the β-arrestins. Methods Mol Biol. 2019;1957:3–8.
   PubMedGoogle Scholar
• Pavlos NJ, Friedman PA. GPCR signaling and trafficking: the long and short of it. Trends Endocrinol Metab. 2017;28:213–226.
   PubMed Web of Science ®Google Scholar
• Hughes CE, Nibbs RJB. A guide to chemokines and their receptors. FEBS J. 2018;285:2944–2971.
   PubMed Web of Science ®Google Scholar
• Steen A, Larsen O, Thiele S, et al. Biased and g protein-independent signaling of chemokine receptors. Front Immunol. 2014;5:277.
   PubMed Web of Science ®Google Scholar
• Kurzejamska E, Sacharczuk M, Landázuri N, et al. Effect of chemokine (C-C Motif) ligand 7 (CCL7) and its receptor (CCR2) expression on colorectal cancer behaviors. Int J Mol Sci. 2019;20:E686.
   PubMed Web of Science ®Google Scholar
• Liao W, Overman MJ, Boutin AT, et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell. 2019;35:559–572.
   PubMed Web of Science ®Google Scholar
• Viney JM, Andrew DP, Phillips RM, et al. Distinct conformations of the chemokine receptor CCR4 with implications for its targeting in allergy. J Immunol. 2014;192:3419–3427.
   PubMed Web of Science ®Google Scholar
• Solari R, Pease JE. Targeting chemokine receptors in disease–a case study of CCR4. Eur J Pharmacol. 2015;763:169–177.
   PubMed Web of Science ®Google Scholar
• Maolake A, Izumi K, Shigehara K, et al. Tumor-associated macrophages promote prostate cancer migration through activation of the CCL22-CCR4 axis. Oncotarget. 2017;8:9739–9751.
   PubMedGoogle Scholar
• Comerford I, Harata-Lee Y, Bunting MD, et al. A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. Cytokine Growth Factor Rev. 2013 Jun;24(3): 269–8.
   PubMed Web of Science ®Google Scholar
• Sriram K, Moyung K, Corriden R, et al. GPCRs show widespread differential mRNA expression and frequent mutation and copy number variation in solid tumors. PLoS Biol. 2019;17:e3000434.
   PubMed Web of Science ®Google Scholar
• Insel PA, Sriram K, Wiley SZ, et al. GPCRomics: GPCR expression in cancer cells and tumors identifies new, potential biomarkers and therapeutic targets. Front Pharmacol. 2018;9:431.
   PubMed Web of Science ®Google Scholar
• Wiley SZ, Sriram K, Salmerón C, et al. GPR68: an emerging drug target in cancer. Int J Mol Sci. 2019;20:E559.
   PubMed Web of Science ®Google Scholar
• Herzig M, Dasgupta P, Kaemmerer D, et al. Comprehensive assessment of GPR68 expression in normal and neoplastic human tissues using a novel rabbit monoclonal antibody. Int J Mol Sci. 2019;20:E5261.
   PubMed Web of Science ®Google Scholar
• Wu A, Maxwell R, Xia Y, et al. Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment. J Neurooncol. 2019;143:241–249.
   PubMed Web of Science ®Google Scholar
• Fouquet G, Guidez S, Richez V, et al. Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myeloma. Oncotarget. 2018;9:23890–23899.
   PubMedGoogle Scholar
• Vela M, Bueno D, González-Navarro P, et al. Anti-CXCR4 antibody combined with activated and expanded natural killer cells for sarcoma immunotherapy. Front Immunol. 2019;10:1814.
   PubMed Web of Science ®Google Scholar
• Innovative Targeting Solutions, Inc. Gallo M, Kang JS, Pigott CR et al. G protein-coupled receptor agonists and methods. EP3077419
   Google Scholar
• Twist Bioscience Corporation; Glanville J. GPCR binding proteins and synthesis thereof. US20190135926
   Google Scholar
• Niwa R, Shoji-Hosaka E, Sakurada M, et al. Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res. 2004;64:2127–2133.
   PubMed Web of Science ®Google Scholar
• Facciabene A, Motz GT, Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162–2171.
   PubMed Web of Science ®Google Scholar
• Ureshino H, Shindo T, Nishikawa H, et al. Effector regulatory T cells reflect the equilibrium between antitumor immunity and autoimmunity in adult T-cell leukemia. Cancer Immunol Res. 2016;4:644–649.
   PubMed Web of Science ®Google Scholar
• Ishitsuka K, Yurimoto S, Tsuji Y, et al. Safety and effectiveness of mogamulizumab in relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2019;102:407–415.
   PubMed Web of Science ®Google Scholar
• Doi T, Muro K, Ishii H, et al. A phase i study of the anti-CC chemokine receptor 4 antibody, mogamulizumab, in combination with nivolumab in patients with advanced or metastatic solid tumors. Clin Cancer Res. 2019;25:6614–6622.
   PubMed Web of Science ®Google Scholar
• Shi L, Lehto SG, Zhu DX, et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor. J Pharmacol Exp Ther. 2016;356:223–231.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Costantini R, et al. Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. J Pain Res. 2017;10:2751–2760.
   PubMed Web of Science ®Google Scholar
• Yuan H, White CS, Silberstein SD. Calcitonin gene-related peptide antagonists in the treatment of episodic migraine. Clin Pharmacol Ther. 2019;105:1121–1129.
   PubMed Web of Science ®Google Scholar
• Brandes JL, Diener HC, Dolezil D, et al. The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response. Cephalalgia. 2019 Dec 9. DOI:10.1177/033310241989455.
   Web of Science ®Google Scholar
• Bussiere JL, Davies R, Dean C, et al. Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol. 2019;106:224–238.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Muralidharan M, Schneider Z, et al. Antibodies to watch in 2020. MAbs. 2020;12:1703531.
   PubMed Web of Science ®Google Scholar
• www.cytodyn.com/newsroom/press-releases/detail/363/cytodyn-announces-acceptance-of-leronlimab-pro-140-data
   Google Scholar
• www.cytodyn.com/pipeline
   Google Scholar
• www.cytodyn.com/newsroom/press-releases/detail/370/cytodyn-reports-early-but-strong-positive-clinical
   Google Scholar
• www.innate-pharma.com/sites/default/files/poster_sitc_2019_iph5401_60x120x2_final_web.pdf
   Google Scholar
• Griffiths K, Binder U, McDowell W, et al. Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4. MAbs. 2019;11:1331–1340.
   PubMed Web of Science ®Google Scholar
• www.humanigen.com/pipeline
   Google Scholar
• Smith EL, Harrington K, Staehr M, et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. 2019;11:7746.
   Web of Science ®Google Scholar
• Hauser AS, Chavali S, Masuho I, et al. Pharmacogenomics of GPCR drug targets. Cell. 2018;172:41–54.
   PubMed Web of Science ®Google Scholar
• Ishchenko A, Wacker D, Kapoor M, et al. Structural insights into the extracellular recognition of the human serotonin 2B receptor by an antibody. Proc Natl Acad Sci U S A. 2017;114:8223–8228.
   PubMed Web of Science ®Google Scholar
• Zhang H, Qiao A, Yang D, et al. Structure of the full-length glucagon class B G-protein-coupled receptor. Nature. 2017;546:259–264.
   PubMed Web of Science ®Google Scholar
• Sanders P, Young S, Sanders J, et al. B. Crystal structure of the TSH receptor (TSHR) bound to a blocking-type TSHR autoantibody. J Mol Endocrinol. 2011;46:81–99.
   PubMed Web of Science ®Google Scholar
• Ravn P, Madhurantakam C, Kunze S, et al. Structural and pharmacological characterization of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem. 2013;288:19760–19772.
   PubMed Web of Science ®Google Scholar
• Toyoda Y, Morimoto K, Suno R, et al. Ligand binding to human prostaglandin E receptor EP4 at the lipid-bilayer interface. Nat Chem Biol. 2019;15:18–26.
   PubMed Web of Science ®Google Scholar
• Peng L, Damschroder MM, Cook KE, et al. Molecular basis for the antagonistic activity of an anti-CXCR4 antibody. MAbs. 2016;8:163–175.
   PubMed Web of Science ®Google Scholar
• Douthwaite JA, Sridharan S, Huntington C, et al. Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1. MAbs. 2015;7:152–166.
   PubMed Web of Science ®Google Scholar
• Lorenzen E, Dodig-Crnković T, Kotliar IB, et al. Multiplexed analysis of the secretin-like GPCR-RAMP interactome. Sci Adv. 2019;5:2778.
   Web of Science ®Google Scholar
• Freudenberg JM, Dunham I, Sanseau P, et al. Uncovering new disease indications for G-protein coupled receptors and their endogenous ligands. BMC Bioinformatics. 2018;19:345.
   PubMed Web of Science ®Google Scholar
• Foster SR, Hauser AS, Vedel L, et al. Discovery of human signaling systems: pairing peptides to G protein-coupled receptors. Cell. 2019;179:895–908.
   PubMed Web of Science ®Google Scholar
• Hancock WW. Chemokines and transplant immunobiology. J Am Soc Nephrol. 2002;13:821–824.
   PubMedGoogle Scholar
• Gao W, Faia KL, Csizmadia V, et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation. 2001;72:1199–1205.
   PubMed Web of Science ®Google Scholar
• Boyé K, Billottet C, Pujol N, et al. Ligand activation induces different conformational changes in CXCR3 receptor isoforms as evidenced by plasmon waveguide resonance (PWR). Sci Rep. 2017;7:10703.
   PubMed Web of Science ®Google Scholar